Hologic

The Aptima HSV 1 & 2 nucleic acid amplification test qualitatively detects and differentiates between HSV-1 and HSV-2 on the automated Panther system.

Despite strong molecular diagnostics product sales growth, the firm's overall diagnostics business was down almost 3 percent year over year.

Hologic said that HCV therapeutic options are evolving rapidly, and the approval will enable physicians to quickly decide on the best treatments.

The firm reported continued strength for MDx product sales across its women's health business and an overall return to growth in international sales.

Hologic's CEO said in December that the blood screening business was a drag on the company's growth. 

The bank rated companies like Thermo Fisher Scientific and Agilent at Buy, Illumina and PerkinElmer at Hold, and Myriad Genetics and Luminex at Sell.

Executives provided updates on their companies at the 35th Annual JP Morgan Healthcare Conference in San Francisco.

Evercore said that Hologic's recent divestiture of its blood screening business limits near-term EPS growth; Piper, however, is looking forward to 2018.

The test, which runs on Hologic's automated Panther system, was granted pre-market approval for HIV-1 viral load monitoring.

Hologic CEO Steve MacMillan said that the deal is so compelling that the firm needed to do it now.

Pages

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.